ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis
NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD
Taking everything into account, ORGO scores 5 out of 10 in our fundamental rating. ORGO was compared to 557 industry peers in the Biotechnology industry. ORGO has an average financial health and profitability rating. ORGO has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ORGO had positive earnings in the past year.
In the past year ORGO had a positive cash flow from operations.
Of the past 5 years ORGO 4 years were profitable.
ORGO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ORGO (-4.37%) is better than 87.61% of its industry peers.
Looking at the Return On Equity, with a value of -5.55%, ORGO belongs to the top of the industry, outperforming 89.95% of the companies in the same industry.
ORGO's Return On Invested Capital of 1.02% is amongst the best of the industry. ORGO outperforms 91.92% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 14.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROIC | 1.02% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
ORGO has a better Operating Margin (1.13%) than 92.10% of its industry peers.
In the last couple of years the Operating Margin of ORGO has declined.
ORGO has a better Gross Margin (75.85%) than 83.66% of its industry peers.
ORGO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ORGO has less shares outstanding than it did 1 year ago.
ORGO has more shares outstanding than it did 5 years ago.
ORGO has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.62 indicates that ORGO is not in any danger for bankruptcy at the moment.
ORGO's Altman-Z score of 4.62 is fine compared to the rest of the industry. ORGO outperforms 76.48% of its industry peers.
ORGO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, ORGO perfoms like the industry average, outperforming 47.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.62 |
ROIC/WACC0.1
WACC10.03%
2.3 Liquidity
ORGO has a Current Ratio of 4.12. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO has a Current ratio of 4.12. This is comparable to the rest of the industry: ORGO outperforms 47.04% of its industry peers.
A Quick Ratio of 3.67 indicates that ORGO has no problem at all paying its short term obligations.
With a Quick ratio value of 3.67, ORGO perfoms like the industry average, outperforming 44.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
ORGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.00%, which is quite impressive.
The earnings per share for ORGO have been decreasing by -37.90% on average. This is quite bad
ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 5.36%.
Measured over the past years, ORGO shows a quite strong growth in Revenue. The Revenue has been growing by 13.05% on average per year.
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
3.2 Future
The Earnings Per Share is expected to grow by 31.62% on average over the next years. This is a very strong growth
ORGO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.53% yearly.
EPS Next Y-61%
EPS Next 2Y16.19%
EPS Next 3Y31.62%
EPS Next 5YN/A
Revenue Next Year4.16%
Revenue Next 2Y8.23%
Revenue Next 3Y10.53%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 47.22, the valuation of ORGO can be described as expensive.
92.28% of the companies in the same industry are more expensive than ORGO, based on the Price/Earnings ratio.
ORGO's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.29.
ORGO is valuated rather expensively with a Price/Forward Earnings ratio of 18.52.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 93.36% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.74. ORGO is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.22 | ||
| Fwd PE | 18.52 |
4.2 Price Multiples
ORGO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ORGO is cheaper than 94.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.12 |
4.3 Compensation for Growth
ORGO has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 31.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.19%
EPS Next 3Y31.62%
5. Dividend
5.1 Amount
No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.25
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners51.78%
Inst Owner Change0%
Ins Owners31.29%
Ins Owner Change1.49%
Market Cap539.11M
Analysts84.44
Price Target6.38 (50.12%)
Short Float %15.91%
Short Ratio7.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)248.79%
Min EPS beat(2)-73%
Max EPS beat(2)570.59%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)13.3%
Revenue beat(4)3
Avg Revenue beat(4)3.87%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.9%
Revenue beat(12)5
Avg Revenue beat(12)0.29%
Revenue beat(16)7
Avg Revenue beat(16)0.94%
PT rev (1m)4.17%
PT rev (3m)4.17%
EPS NQ rev (1m)-66.67%
EPS NQ rev (3m)-400%
EPS NY rev (1m)73.33%
EPS NY rev (3m)23.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.22 | ||
| Fwd PE | 18.52 | ||
| P/S | 1.18 | ||
| P/FCF | N/A | ||
| P/OCF | 121.56 | ||
| P/B | 1.46 | ||
| P/tB | 1.65 | ||
| EV/EBITDA | 19.12 |
EPS(TTM)0.09
EY2.12%
EPS(NY)0.23
Fwd EY5.4%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)0.03
OCFY0.82%
SpS3.62
BVpS2.9
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROCE | 1.29% | ||
| ROIC | 1.02% | ||
| ROICexc | 1.4% | ||
| ROICexgc | 1.63% | ||
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3Y-38.4%
ROICexcg growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score6
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 65.96% | ||
| Cap/Sales | 2.49% | ||
| Interest Coverage | 1.44 | ||
| Cash Conversion | 19.68% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 4.62 |
F-Score6
WACC10.03%
ROIC/WACC0.1
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-61%
EPS Next 2Y16.19%
EPS Next 3Y31.62%
EPS Next 5YN/A
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
Revenue Next Year4.16%
Revenue Next 2Y8.23%
Revenue Next 3Y10.53%
Revenue Next 5YN/A
EBIT growth 1Y-59.06%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year510.28%
EBIT Next 3Y111.89%
EBIT Next 5YN/A
FCF growth 1Y57.36%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-75.86%
OCF growth 3Y-38.8%
OCF growth 5YN/A